Skip to Content
Merck
All Photos(1)

Key Documents

SML2601

Sigma-Aldrich

dTAG-13

≥98% (HPLC), powder, degradation tag  (dTAG) system

Synonym(s):

(2S)-(1R)-3-(3,4-Dimethoxyphenyl)-1-(2-(2-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)amino)-2-oxoethoxy)phenyl)propyl 1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate, d-TAG-13

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C57H68N4O15
CAS Number:
Molecular Weight:
1049.17
UNSPSC Code:
12352200
NACRES:
NA.77

product name

dTAG-13, ≥98% (HPLC)

ligand

thalidomide

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

O=C(O[C@@H](C1=C(C=CC=C1)OCC(NCCCCCCOC2=C(C3=CC=C2)C(N(C3=O)C4CCC(NC4=O)=O)=O)=O)CCC5=CC=C(C(OC)=C5)OC)[C@@H]6CCCCN6C([C@H](C7=CC(OC)=C(C(OC)=C7)OC)CC)=O

Biochem/physiol Actions

dTAG-13 is a degradation tag (dTAG) system heterobifunctional degrader composed of an E3 ubiquitin ligase cereblon (CRBN)-binding thalidomide moiety and an FKBP12(F36V) mutant-specific ligand AP1867 void of affinity for endogenous (wild-type) FKBP12, allowing selective degradation of target proteins of interest when expressed as an FKBP12(F36V) in-frame fusion (by transgene expression or locus-specific knock-in) by bridging them with CRBN for ubiquitination. dTAG-13 is shown to potently degrade FKBP12F36V-MELK(sg3R) in MDA-MB-468 cells (100 nM for 4 hrs) as well as ENL-FKBP12F36V-HA, but not endogenous ENL, in MV4;1 cells (500 nM for 0.5-1 hrs).

Other Notes

Contains a mixture of diastereomers. This product has not been tested in cellular degradation assays.

Legal Information

Sold with permission under license from Dana Farber Cancer Institute.

related product

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Behnam Nabet et al.
Nature chemical biology, 14(5), 431-441 (2018-03-28)
Dissection of complex biological systems requires target-specific control of the function or abundance of proteins. Genetic perturbations are limited by off-target effects, multicomponent complexity, and irreversibility. Most limiting is the requisite delay between modulation to experimental measurement. To enable the
Transcription control by the ENL YEATS domain in acute leukaemia
Erb MA, Scott TG, Li BE, et al.
Nature, 543(7644), 270-274 (2017)
MELK is not necessary for the proliferation of basal-like breast cancer cells
Huang HT, Seo HS, Zhang T, et al.
eLife, 6, e26693-e26693 (2017)
Michael A Erb et al.
Nature, 543(7644), 270-274 (2017-02-28)
Recurrent chromosomal translocations producing a chimaeric MLL oncogene give rise to a highly aggressive acute leukaemia associated with poor clinical outcome. The preferential involvement of chromatin-associated factors as MLL fusion partners belies a dependency on transcription control. Despite recent progress
The dTAG system for immediate and target-specific protein degradation.
Nabet B, Roberts JM, Buckley DL, et al.
Nature Chemical Biology, 14(5), 431-441 (2018)

Related Content

Targeted protein degradation (TPD) is an emerging drug discovery strategy that uses small-molecules, such as proteolysis-targeting chimeras (PROTACs), to eradicate targeted proteins linked to disease from cells.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service